A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer

View/ Open
Author
Lagerweij, Tonny
Hiddingh, Lotte
Biesmans, Dennis
Crommentuijn, Matheus H.W.
Cloos, Jacqueline
Li, Xiao-Nan
Kogiso, Mari
Vandertop, W. Peter
Noske, David P.
Kaspers, Gertjan J.L.
Würdinger, Tom
Hulleman, Esther
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.18632/oncotarget.7980Metadata
Show full item recordCitation
Lagerweij, T., L. Hiddingh, D. Biesmans, M. H. Crommentuijn, J. Cloos, X. Li, M. Kogiso, et al. 2016. “A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer.” Oncotarget 7 (24): 35776-35788. doi:10.18632/oncotarget.7980. http://dx.doi.org/10.18632/oncotarget.7980.Abstract
Treatment of medulloblastoma in children fails in approximately 30% of patients, and is often accompanied by severe late sequelae. Therefore, more effective drugs are needed that spare normal tissue and diminish long-term side effects. Since radiotherapy plays a pivotal role in the treatment of medulloblastoma, we set out to identify novel drugs that could potentiate the effect of ionizing radiation. Thereto, a small molecule library, consisting of 960 chemical compounds, was screened for its ability to sensitize towards irradiation. This small molecule screen identified the flavonoid quercetin as a novel radiosensitizer for the medulloblastoma cell lines DAOY, D283-med, and, to a lesser extent, D458-med at low micromolar concentrations and irradiation doses used in fractionated radiation schemes. Quercetin did not affect the proliferation of neural precursor cells or normal human fibroblasts. Importantly, in vivo experiments confirmed the radiosensitizing properties of quercetin. Administration of this flavonoid at the time of irradiation significantly prolonged survival in orthotopically xenografted mice. Together, these findings indicate that quercetin is a potent radiosensitizer for medulloblastoma cells that may be a promising lead for the treatment of medulloblastoma in patients.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094961/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:29626020
Collections
- HMS Scholarly Articles [17875]
Contact administrator regarding this item (to report mistakes or request changes)